Background. The benefits and costs of a treatment are typically heterogeneous across individual patients. Randomized clinical trials permit the examination of individualized treatment benefits over the trial horizon but extrapolation to lifetime horizon usually involves combining trial-based individualized estimates of short-term risk reduction with less detailed (less granular) population life tables. However, the underlying assumption of equal post-trial life expectancy for low-and high-risk patients of the same sex and age is unrealistic. We aimed to study the influence of unequal granularity between models of short-term risk reduction and life expectancy on individualized estimates of cost-effectiveness of aggressive thrombolysis for patients with an acute myocardial infarction. Methods. To estimate life years gained, we multiplied individualized estimates of short-term risk reduction either with less granular and with equally granular post-trial life expectancy estimates. Estimates of short-term risk reduction were obtained from GUSTO trial data (30,510 patients) using logistic regression analysis with treatment, sex, and age as predictor variables. Life expectancy estimates were derived from sex-and agespecific US life tables. Results. Based on sex-and agespecific, short-term risk reductions but average population life expectancy (less granularity), we found that aggressive thrombolysis was cost-effective (incremental cost-effectiveness ratio below $50,000) for women above age 49 y and men above age 53 y (92% and 69% of the population, respectively). Considering sex-and age-specific short-term mortality risk reduction and correspondingly sex-and agespecific life expectancy (equal granularity), aggressive thrombolysis was cost-effective for men above age 45 y and women above age 50 y (95% and 76% of the population, respectively). Conclusions. Failure to model short-term risk reduction and life expectancy at an equal level of granularity may bias our estimates of individualized cost-effectiveness and misallocate resources. Key words: outcomes research; translating research into practice; formulary decision making. (Med Decis Making 2017;37:770-778) T he cost-effectiveness of a treatment has increasingly been recognized to be heterogeneous across individual patients. [1] [2] [3] Interventions that are cost-effective on average may be of very low value for many (even most) patients. An estimation of individualized (or stratified) cost-effectiveness can thus support a more efficient distribution of resources, but requires an individualized estimation of treatment benefit, treatment harms, treatment costs, and patient preferences. [4] [5] [6] [7] [8] Individualized treatment benefit estimation is often focused on heterogeneity in short-term mortality risk differences under different treatment regimens. These differences are commonly based on outcome data from a clinical trial with excellent information on patient characteristics. However, the individualized, long-term treatment benefit also depends on the post-trial life expectancy. Because post-trial survival information is generally lacking, post-trial life expectancy is usually derived from less granular (less detailed) population life tables. However, the underlying assumption of equal posttrial life expectancy for low-and high-risk patients of the same sex and age is unrealistic.
For example, in economic analyses of different thrombolytic reperfusion therapies to restore blood flow after acute myocardial infraction (MI), the individualized cost-effectiveness estimates of treatment with accelerated tissue plasminogen activator (t-PA) rather than streptokinase were based on predictions of the 30-day mortality reduction using 11 predictors, while post-trial life expectancies were derived from sex-and age-specific life tables. 9 Measures of heart attack severity (such as electrocardiographic infarction-size and location, and vital signs) were incorporated into the prediction of short-term mortality (and benefit), but no such measures were included in the estimation of long-term survival, even though infarct size and severity undoubtedly contribute to longer-term mortality. [10] [11] [12] Consequently, the longterm treatment benefit in terms of life years may have been overestimated for high-risk patients and underestimated for low-risk patients.
In general, age, severity of disease, and the presence of comorbidities are typically strong determinants of both short-term and long-term survival; i.e., patients at high short-term mortality risk likely have a low life expectancy after short-term survival. Therefore, to estimate the long-term treatment benefit for an individual patient, the short-term risk reduction and the post-trial life expectancy should be individualized consistently; i.e., with equal granularity for all determinants of mortality risk.
Although short-term and long-term risk models are ideally based on the same level of detail in information, we do not know the impact of combining detailed short-term risk models with less granular long-term risk models. It is therefore essential to explore and understand the impact of the imbalance between the level of granularity in models of shortterm risk and life expectancy. We aimed to study the influence of unequal granularity between models of short-term risk reduction and life expectancy on individualized cost-effectiveness estimates.
METHODS
We compared individualized cost-effectiveness estimates of t-PA treatment v. streptokinase treatment after an acute myocardial infarction for different models of short-term risk and post-trial life expectancy. To obtain life years gained at the individual level, we multiplied estimates of short-term risk reductions either with less granular or equally granular post-trial life expectancy estimates. We adopted a relatively simple methodology to analyze the cost-effectiveness analysis of t-PA treatment v. streptokinase treatment. 9, 13 We analyzed 30,510 patients with acute myocardial infarction who were randomized to treatment with different forms of thrombolysis in the Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Coronary Arteries (GUSTO) trial.
First, we estimated the short-term mortality risk reduction of t-PA treatment using a logistic regression model with treatment, sex, and age as predictor variables for 30-d mortality. Thus, the absolute risk reduction of t-PA treatment was estimated by the predicted 30-d mortality without t-PA treatment minus the predicted 30-d mortality with t-PA treatment, assuming a constant relative treatment effect. 14 Analogous to most trials, long-term survival data was not available for patients in the GUSTO trial. We estimated post-trial life expectancy from sex-and age-specific US life tables in combination with an additional 2% yearly excess hazard to capture the increased long-term mortality risk of cardiovascular patients. 9, 15 To obtain estimates of life years gained for individual patients, sex-and agespecific estimates of short-term risk reductions were either multiplied with sex-and age-specific posttrial life expectancy estimates (equal level of granularity) or with the average of the post-trial life expectancy estimates in our patient population (less granularity). To interpret the difference between using the population average life expectancy v. a sex-and age-specific life expectancy, we first compared estimates of life years gained and incremental cost-effectiveness ratios (ICERs) for quintiles of short-term mortality risk. We further extended the comparison of ICERs to percentiles of short-term mortality risk for individual female and male patients separately, and to patients grouped by their sex and age decade.
Second, to explore the use of additional risk information about the severity of heart failure, we included the Killip classification for estimation of the short-term mortality reduction of t-PA treatment. 16 Because patients with higher Killip class are known to also have worse long-term prognosis, 11, 12 we analyzed the sensitivity of costeffectiveness estimates using the Killip class for an estimation of post-trial life expectancy. Hereto, we multiplied post-trial yearly mortality hazards with short-term, trial-based hazard ratios of Killip classes II, III and IV v. Killip class I, and calibrated the excess hazard to produce an equal average life expectancy of the overall patient population. Because the assumption of equal associations for both short-term and long-term mortality with the Killip class may be too rigorous, we also multiplied with the square root of the short-term hazard ratios (i.e., half the effect size) to represent a milder association of long-term risk with the Killip class. To obtain estimates of life years gained and ICERs for individual patients, the sex-, age-, and Killip classspecific estimates of short-term risk reductions were either multiplied with sex-, age-and Killip class-specific post-trial life expectancy estimates (equal level of granularity) or with sex-and age-specific post-trial life expectancy estimates (less granularity). We compared the resulting ICERs by percentiles of shortterm mortality risk, and by patients grouped according to their sex, age decade and Killip class.
Incremental costs of t-PA treatment were assumed to be constant across patients at $2,700, and not different for the t-PA group after the first year. 9 To estimate life-expectancy with and without treatment over a life-time time horizon, estimates of 30-d mortality were combined with annual rates of mortality, with discounting at 3% per year. Treatment with t-PA was considered cost-effective for incremental costs per life year gained falling below $50,000. All analyses were done with R statistical software. 17 
RESULTS
Short-term mortality was significantly associated with the treatment (t-PA v. Streptokinase), and with the sex, age, and Killip class of the patient (Table 1) . Treatment with t-PA reduced the overall short-term mortality by 1.0% (6.3% with t-PA v. 7.3% with Streptokinase). With an average discounted posttrial life expectancy of 12.3 y (undiscounted, 16.9 y) and fixed incremental costs of $2,700, t-PA treatment was on average cost-effective at the $50,000 threshold (ICER $21,895).
Based on sex-and age-specific short-term risk reductions but average population life expectancy, there was a substantial heterogeneity in expected life years gained between the lowest and highest risk quintiles of short-term mortality risk (0.03 life years in 1 st quintile v. 0.32 life years in 5 th quintile; upper panel of Figure 1 ). The ICER in the lowest risk quintile exceeded the $50,000 threshold (lower panel of Figure 1 ). When both short-term mortality risk reduction and life expectancy were sex-and age-specific (i.e., equal in level of granularity), the difference in life years gained between the lowest and highest risk quintile was attenuated (0.04 life years in first quintile v. 0.20 life years in fifth quintile; upper panel of Figure 1 ). The difference between the ICERs in the first and fifth quintiles decreased accordingly (lower panel of Figure 1 ).
The attenuation of ICER heterogeneity is further visualized by percentiles of short-term mortality risk for female and male patients separately ( Figure  2 ). When only the short-term mortality risk reduction was modelled as sex-and age-specific, t-PA treatment was cost-effective for women above 49 y (92% of the female population; left panel of Figure  2 ) and men above 53 y (69% of the male population; right panel of Figure 2 ). ICER estimates in female patients were lower because of a higher short-term mortality reduction. When both short-term mortality risk reduction and life expectancy were modelled as sex-and age-specific, the heterogeneity in cost-effectiveness estimates decreased. Thus, cost-effectiveness of t-PA treatment was extended to women above 45 y (95% of the female population; left panel of Figure 2 ) and men above 50 y (76% of the male population; right panel of Figure 2 ). When future life years were not discounted, ICERs decreased but the attenuation of ICER heterogeneity was stronger, because the impact of life expectancy assumptions was not moderated by discounting ( Figure 3 ). The decrease in heterogeneity of costeffectiveness-when both short-term mortality risk reduction and life expectancy were modelled as sex-and age-specific-was also clearly observable in the smaller difference between the ICER of patients in the oldest age group and the ICER of patients in the youngest age group (Table 2) .
Specifically, the ICER decreased from $176 thousand to $126 thousand for male patients and from $131,000 idem to $90,000 for female patients younger than 40 y, but increased from $7 thousand to $16 thousand for male patients and from $6 thousand to $12 thousand for female patients above 80 y. The effect of negative correlation between mortality risk reduction and life expectancy for individual patients is further illustrated by adding Killip classification as a risk factor. As expected, the effect of applying short-term Killip class hazard ratios to post-trial mortality was stronger with increasing Killip class and with stronger assumptions about the long-term mortality effects of Killip class (Table  3 ; Figure 4 ). When short-term and long-term mortality effects of Killip class were assumed equal, t-PA treatment was not cost-effective for older patients with Killip class IV (females above 79 y; males above 80 y; Table 3 ; lowest right panel of Figure 4 ) because of a low post-trial life expectancy. t-PA treatment was cost-effective for most other patients with worse heart failure than Killip class I.
DISCUSSION
We present 2 examples of the effect of a negative correlation between the reduction in short-term mortality and post-trial life expectancy at the individual level; i.e., patients of a high age have a high short-term mortality risk reduction but a low life expectancy, and similarly, patients in severe Killip class IV have a high-risk reduction but a low life expectancy. These examples illustrate the substantial impact on individualized cost-effectiveness estimates of modeling individualized instead of average long-term life expectancy; e.g., the estimate of life years gained for the 20% of patients with the highest sex-and age-specific short-term risk decreased from 0.32 to 0.20 when using sex-and age-specific life expectancy instead of average population life expectancy. Consequently, when short-term risk reduction and long-term life expectancy are modelled at unequal levels of granularity, individualized estimates of cost-effectiveness are biased, and heterogeneity in cost-effectiveness between low-risk and high-risk patients (or quintiles of patients) is overestimated.
Because short-term risk models can frequently be developed on detailed clinical data, and because life expectancy functions are typically obtained from life tables, there is often an imbalance in the level of granularity, which leads to an exaggeration of the true heterogeneity of individualized costeffectiveness (and the expected value of individualized care 4 ). One example of combining individualized short-term risk estimates with less granular group-level life expectancy estimates can be found in the cost-effectiveness analysis of CT Screening in the NLST, 18 which considered risk-based subgroups (quintiles), following the increased attention for individualized screening. [19] [20] [21] Risk quintiles were based on the risk factors of age; race/ethnicity; education; body-mass index; chronic obstructive pulmonary disease; personal history of cancer; family history of lung cancer; and smoking status, intensity, duration, and quit time. 20 Within-trial life-years were observed for approximately 6 y of follow-up. Post-trial life-years were based on 2009 US life-tables, adjusted for smoking status and stage-specific lung cancer mortality but not for the other lung cancer risk factors. This inconsistency may cause overestimation of the post-trial life-years Note: Based on sex-and age-specific short-term mortality risk reduction, in combination with average population life expectancy (''Without longterm age effect'') or sex-and age-specific life expectancy (''Long-term age effect from life table'').
Figure 2
Incremental cost-effectiveness ratio (ICER) by percentile of sex-and age-specific short-term mortality risk for female and male patients. Patients are ordered from low short-term mortality risk (Percentile 0) to high short-term mortality risk (Percentile 100). Data are based on average population life expectancy (grey lines) and on sex-and age-specific life expectancy (black lines). The grey line is below $50,000 for women above 49 y and for men above 53 y. The black line is below $50,000 for women above 45 y and for men above 50 y. Figure 3 Undiscounted incremental cost-effectiveness ratio (ICER) by percentile of sex-and age-specific short-term mortality risk for female and male patients. Patients are ordered from low short-term mortality risk (Percentile 0) to high short-term mortality risk (Percentile 100). Data are based on average population life expectancy (grey lines) and on sex-and age-specific life expectancy (black lines). The grey line is below $50,000 for women above 45 y and for men above 49 y. The black line is below $50,000 for women above 38 y and for men above 44 y. in the highest risk quintiles, as some risk factors are ignored for their impact on reducing life-expectancy; e.g., smoking intensity. 22 Estimates of longterm benefit may have been too favorable in the 2 highest lung cancer risk quintiles. The impact on stratified cost-effectiveness estimates of CT screening will probably be less than that in our case study of t-PA cost-effectiveness, because the posttrial life expectancy estimates are less influential with a longer trial follow-up (6 y v. 30 d).
We raise awareness that using simple models for life expectancy estimates may lead to an Figure 4 Incremental cost-effectiveness ratio (ICER) by percentile of sex-, age-and Killip class-specific short-term mortality risk for male patients. Patients are ordered from low short-term mortality risk (Percentile 0) to high short-term mortality risk (Percentile 100). Data are based on sex-and age-specific life expectancy (grey lines) and on sex-, age-and Killip class-specific life expectancy (black lines). Short-term Killip hazard ratios (half the effect size, i.e., the square root of the short-term hazard ratios on the left-hand side) were applied to long-term mortality hazards for individual patients.
overestimation of individualized cost-effectiveness heterogeneity. On the other hand, using simpler models for short-term risk reduction estimates may lead to underestimation of the individualized costeffectiveness heterogeneity. Instead of limiting the individualization of short-term risk, we would like to promote a better understanding of the consequences of unequally granular risk models by means of sensitivity analysis. In our case study, we accounted for correlation between short-term and long-term mortality due to severity of heart failure by applying short-term risk ratios of Killip classes to long-term post-trial mortality. Because long-term survival data was not available for patients in the GUSTO trial, it is unclear whether including shortterm risk information of Killip classes would lead to more appropriate post-trial life expectancy estimates. However, it may be a practical approach to analyze the sensitivity of individualized costeffectiveness estimates when information about the effects of short-term risk factors on long-term mortality is missing. It prevents overenthusiasm on the value of the individualization of risk estimates, which would occur by considering short-term impact only. Ideally, the effects of short-term risk factors on long-term mortality are derived from a comprehensive data set. Using published models may also be sensible, and better than ignoring the impact of predictors on long-term life expectancy. Regardless of the approach that is chosen for harmonizing the granularity of short-term and long-term mortality, the uncertainty in individualized costeffectiveness estimates depends on the uncertainty in estimates of both short-term and long-term mortality. As this paper is about biases rather than uncertainty, quantification of uncertainty in individualized cost-effectiveness estimates requires further research.
We assumed a constant relative treatment effect in our analyses, which implies that the absolute risk reduction of t-PA treatment is an increasing function of baseline risk. 9, 13, 14 Relative treatment effect heterogeneity-i.e., variation of relative treatment effect across individuals-could be incorporated in an analysis of individual cost-effectiveness, but may be sensitive to the pitfalls of subgroup analysis. 23 Individualizing cost-effectiveness requires valid prediction models, both in terms of discrimination and calibration. Overestimation of the average risk (miscalibration) leads to overoptimistic costeffectiveness estimates. When regression model coefficients are overestimated, the discriminative ability is overoptimistic. 24 Hence, differences in individual cost-effectiveness between individuals are overstated. Further research is necessary to study the relation between classical measures for model performance such as the area under the receiver operating characteristic curve (AUC) and the value of using individualized cost-effectiveness estimates for guiding treatment decisions.
Heterogeneity of patient preferences may also be an important aspect when individualizing costeffectiveness assessments. For example, the decision whether to screen for prostate cancer or treat patients with localized prostate cancer depends heavily on patients' individual valuations of the outcomes of treatment, because screening and treatment result in life expectancy gain but qualityadjusted life expectancy loss. 25, 26 We focused on the relationship between baseline risk and life expectancy after MI. Given that quality of life may be correlated with baseline risk, individualized estimates of utility are desirable, again at an equal level of granularity. 27 In conclusion, failure to model short-term risk reduction and life expectancy at an equal level of granularity may bias individualized estimates of cost-effectiveness, exaggerate the true heterogeneity of individualized cost-effectiveness, and therefore misallocate resources when risk models are used for targeting care. Individualized cost-effectiveness analysis should be based on estimates of long-term life expectancy at the same level of granularity as the estimates of the short-term risk reduction.
